MCAS, POTS, and EDS: ImmunoPsychiatry Training Booklet — Recognition, Workup, and Management for Psychiatry Residents and PMHNPs
- Dr. Renee Parisi PMHNP
- 22 hours ago
- 13 min read
PART 1: WHY THIS MATTERS FOR PSYCHIATRY
The Problem
Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and Hypermobile Ehlers-Danlos Syndrome (hEDS) frequently co-occur as a clinical triad. These conditions produce neuropsychiatric symptoms—anxiety, panic, depression, insomnia, cognitive impairment ("brain fog")—that overlap with and are often misdiagnosed as primary psychiatric disorders. Depression-anxiety symptoms occur in 40–60% of patients with mast cell disorders, and cognitive impairment is reported in nearly 39%.
In rural settings, patients with this triad are frequently labeled "somatoform" or "conversion disorder" and referred to psychiatry as a diagnostic endpoint. The average diagnostic delay for mast cell activation disease is measured in decades. Psychiatry can serve as a diagnostic safety net—not a dead end.
Key Principle: The DSM-5 explicitly states that "it is not appropriate to give an individual a mental disorder diagnosis solely because a recognized medical condition cannot be demonstrated." Somatic symptom disorder requires positive criteria—excessive thoughts, feelings, or behaviors related to symptoms—not merely the absence of a medical explanation.
PART 2: UNDERSTANDING THE THREE CONDITIONS
A. Mast Cell Activation Syndrome (MCAS)
Mast cells are immune cells that reside in connective tissue throughout the body. In MCAS, they inappropriately degranulate in response to triggers (food, heat, stress, emotion, mechanical stimuli, medications), releasing histamine, prostaglandins, leukotrienes, heparin, cytokines, and other proinflammatory molecules.
Symptoms affect ≥2 organ systems episodically:
- Cardiovascular: Hypotension, tachycardia, syncope/presyncope
- Dermatologic: Flushing, urticaria (hives), pruritus (itching)
- Gastrointestinal: Crampy abdominal pain, diarrhea, nausea
- Respiratory: Wheezing, dyspnea, stridor
- Neuropsychiatric: Anxiety, panic, depression, brain fog, insomnia
Common triggers: Heat, cold, stress, alcohol, certain foods, exercise, hormonal fluctuations, physical pressure, medications (NSAIDs, opioids, certain anesthetics).
B. Postural Orthostatic Tachycardia Syndrome (POTS)
POTS is a form of autonomic dysfunction characterized by an excessive heart rate increase upon standing (≥30 bpm in adults, ≥40 bpm in ages 12–19) within 10 minutes, without orthostatic hypotension (BP drop >20/10 mmHg). Symptoms include lightheadedness, palpitations, presyncope, exercise intolerance, brain fog, and fatigue—often worsening in heat or in the morning.
POTS subtypes include:
- Neuropathic (partial autonomic neuropathy)
- Hyperadrenergic (standing norepinephrine >600 pg/mL)
- Mast cell activation phenotype (MCAS-driven)
- Autoimmune (ganglionic AChR antibodies)
C. Hypermobile Ehlers-Danlos Syndrome (hEDS)
hEDS is a hereditary connective tissue disorder characterized by generalized joint hypermobility, chronic pain, soft/velvety skin, easy bruising, and frequent subluxations/dislocations. The abnormal connective tissue microenvironment may alter mast cell behavior, as mast cells differentiate and mature within connective tissue.
The 2017 International EDS Consortium diagnostic criteria require:
1. Generalized joint hypermobility (Beighton score ≥5 if ≤50 years; ≥4 if >50 years)
2. Two or more systemic features of a connective tissue disorder
3. Exclusion of alternative diagnoses
PART 3: THE SCIENCE — HOW HISTAMINE CONNECTS THESE CONDITIONS TO PSYCHIATRIC SYMPTOMS
Histamine as a Central Mediator
Histamine is both a peripheral inflammatory mediator and a central neurotransmitter. It acts through four receptor
H1:
Brain, smooth muscle, endothelium
Vasodilation, bronchoconstriction, pruritus, CNS arousal/anxiety
H2:
Gastric parietal cells, heart, brain
Gastric acid secretion, cardiac chronotropy
H3:
CNS (presynaptic)
Modulates release of histamine, serotonin, dopamine, norepinephrine, glutamate
H4:
Immune cells
Chemotaxis, immune regulation
Histamine and Anxiety: Histaminergic neurons in the hypothalamus project to the bed nucleus of the stria terminalis (BNST), a key node in stress and anxiety circuitry. Histamine in this region produces anxiogenic effects. Brain mast cells themselves have been implicated in anxiety-like behavior.
Histamine and Insomnia: The histaminergic system is one of the primary wake-promoting systems in the brain. Excessive histaminergic tone disrupts sleep architecture. This is why H1 antihistamines (diphenhydramine, hydroxyzine) are sedating.
Histamine and Depression: H3 receptors regulate the release of serotonin, dopamine, and glutamate—all implicated in major depressive disorder. Histamine also activates the enzyme indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan metabolism away from serotonin synthesis toward neurotoxic kynurenine metabolites.
Neuroinflammation and Psychiatric Illness
A growing body of evidence supports the concept that microscopic inflammation in the brain and nervous system contributes to psychiatric illness:
1. Microglial activation: Activated microglia release proinflammatory cytokines (TNF-α, IL-1β, IL-6) that damage neurons and disrupt synaptic function.
2. Cytokine-mediated neurotransmitter disruption: Proinflammatory cytokines impair monoamine synthesis by damaging tetrahydrobiopterin (BH4), an essential cofactor for serotonin, dopamine, and norepinephrine production.
3. Blood-brain barrier disruption: Brain mast cells can increase BBB permeability through release of proteases (MMP-9), allowing peripheral inflammatory mediators to enter the CNS.
4. Bidirectional loop: Depression facilitates inflammatory reactions, and inflammation promotes depression—creating a self-reinforcing cycle.
The Vagus Nerve: The Missing Link
The vagus nerve is the primary neural conduit connecting peripheral inflammation to brain function:
- The cholinergic anti-inflammatory pathway (CAP): Efferent vagal fibers release acetylcholine, which suppresses release of TNF-α and other proinflammatory cytokines. When vagal tone is reduced (as in POTS and other dysautonomias), this anti-inflammatory brake is weakened.
- Afferent signaling: ~80% of vagal fibers are afferent, carrying information from the gut, heart, and viscera to the brainstem, which relays to limbic and cortical regions governing mood and anxiety.
- Gut-brain axis: The vagus nerve transmits signals from the gut microbiome to the CNS. Stress alters gut permeability and microbiome composition, which modulates vagal signaling and neuroinflammation.
Clinical Implication for Trainees: In patients with the MCAS/POTS/EDS triad, psychiatric symptoms may not represent primary psychiatric illness but rather the neuropsychiatric manifestation of systemic mast cell-mediated inflammation, autonomic dysfunction, and impaired vagal anti-inflammatory regulation.
---
PART 4: BEDSIDE SCREENING — WHAT YOU CAN DO IN ANY OFFICE
A. The Beighton Score (Screening for hEDS)
This is a 9-point physical exam requiring no equipment. Each item is worth 1 point. Perform the following maneuvers:
Passive dorsiflexion of 5th finger >90° — LEFT
Passive dorsiflexion of 5th finger >90° — RIGHT
Passive thumb-to-forearm apposition — LEFT
Passive thumb-to-forearm apposition — RIGHT
Elbow hyperextension >10° — LEFT
Elbow hyperextension >10° — RIGHT
Knee hyperextension >10° — LEFT
Knee hyperextension >10° — RIGHT
Palms flat on floor with knees extended
Interpretation:
- ≥5 (age ≤50) or ≥4 (age >50) = Generalized joint hypermobility → proceed to full 2017 hEDS criteria
- A positive Beighton score alone does not diagnose hEDS; systemic features (Criterion 2) and exclusion of alternatives (Criterion 3) are also required
B. The Active Stand Test (Screening for POTS)
Equipment needed: Blood pressure cuff with heart rate display (or pulse oximeter), timer, flat surface for the patient to lie down.
Protocol:
1. Patient rests supine for 5–10 minutes in a quiet room
2. Record baseline heart rate (HR) and blood pressure (BP)
3. Patient stands up and remains standing quietly (no walking, no leaning)
4. Record HR and BP at 1, 3, 5, and 10 minutes
Recording Sheet:
Time Point | HR (bpm) |Systolic BP |Diastolic BP | Symptoms
Supine baseline (after 5–10 min rest)
Standing — 1 min
Standing — 3 min
Standing — 5 min
Standing — 10 min
Interpretation:
- POTS: HR increase ≥30 bpm (≥40 bpm if age 12–19) within 10 minutes of standing, WITHOUT orthostatic hypotension (BP drop >20/10 mmHg)
- Orthostatic hypotension: Sustained BP drop ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes → different diagnosis (autonomic failure)
- The active stand test is more specific than tilt table testing (79% vs. 23%) and is considered sufficient for diagnosis in most cases
Safety: Have a chair nearby. Stop the test if the patient becomes presyncopal. Document symptoms at each time point.
C. MCAS Symptom Screening Checklist
Ask the patient about episodic (not constant) symptoms in each domain. Document triggers and temporal patterns.
Organ System | Symptoms to Screen For | Present? Episodic? Triggers?
Cardiovascular: Flushing, palpitations, lightheadedness, near-fainting
Dermatologic: Hives, itching, flushing, angioedema
Gastrointestinal: Crampy abdominal pain, diarrhea, nausea, bloating
Respiratory: Wheezing, shortness of breath, nasal congestion
Neuropsychiatric: Brain fog, anxiety, panic, insomnia, headache
Musculoskeletal: Bone/joint pain, muscle aching
Key diagnostic clue: Symptoms affecting ≥2 organ systems that are episodic, recurrent, and triggered by identifiable stimuli (heat, stress, food, exercise, hormonal changes).
PART 5: LABORATORY WORKUP
What You Can Order from a Rural Setting
Tier 1 — Available everywhere (standard reference labs):
- Serum tryptase (baseline) — available through Quest, LabCorp, and most reference labs
- CBC with differential
- Comprehensive metabolic panel
- TSH
- CRP or hs-CRP, ESR
- IgE level
Tier 2 — Available through reference labs but may require special handling:
- Serum tryptase during an acute episode (draw within 1–4 hours of symptoms; compare to baseline using formula: acute ≥ 1.2 × baseline + 2 ng/mL)
- Plasma histamine (must be processed on ice — less reliable)
Tier 3 — May require specialist ordering or specialized lab:
- 24-hour urine: N-methylhistamine, 11β-prostaglandin F2α (most sensitive single marker), leukotriene E4 — all normalized to creatinine
- Supine and upright plasma catecholamines (for POTS subtyping)
- Ganglionic acetylcholine receptor (AChR) antibodies (autoimmune POTS)
- EDS gene panel or whole exome sequencing
Tier 4 — Requires specialist referral:
- Formal autonomic function testing (QSART, thermoregulatory sweat test)
- Bone marrow biopsy (if [systemic mastocytosis](/rare-disease/systemic-mastocytosis) suspected)
- Echocardiography (screen for mitral valve prolapse, aortic root dilation in EDS)
PART 6: THE TWO DIAGNOSTIC FRAMEWORKS FOR MCAS
Understanding both frameworks is essential for rural practice.
Consensus-1 (Valent, Akin et al., 2012; endorsed by AAAAI)
ALL FOUR criteria required:
1. ☐ Episodic symptoms consistent with mast cell mediator release affecting ≥2 organ systems
2. ☐ Decrease in frequency/severity with antimediator therapy
3. ☐ Elevation of a validated serum or urinary mast cell mediator (tryptase, N-methylhistamine, 11β-PGF2α, or LTE4)
4. ☐ Exclusion of other causes
Consensus-2 (Afrin, Molderings et al., 2011/2021)
MAJOR criterion required:
- ☐ A constellation of clinical complaints attributable to pathologically increased mast cell activity (multisystem, episodic)
PLUS ≥1 MINOR criterion:
- ☐ Elevated mast cell counts in tissue (≥20/hpf)
- ☐ Abnormal spindle-shaped mast cell morphology
- ☐ Abnormal CD2/CD25 expression on mast cells
- ☐ Mast cell genetic changes (e.g., KIT mutations)
- ☐ Evidence of above-normal mast cell mediator levels
- ☐ Symptomatic response to inhibitors of mast cell activation or mediator production/action
Key Difference
Consensus-2 allows a therapeutic response to antimediator therapy (antihistamines, mast cell stabilizers) to serve as a minor diagnostic criterion. Consensus-1 requires objective laboratory documentation of elevated mediators.
When to Use Which
In rural settings where Tier 3 testing is unavailable, Consensus-2 provides a structured clinical framework for preliminary diagnosis. The therapeutic trial criterion requires no specialized laboratory.
Important Caveats:
- Consensus-2 is NOT universally accepted. The AAAAI endorses Consensus-1 only.
- Therapeutic response is not specific — antihistamines improve symptoms in many conditions that are not MCAS.
- Always document as: "Preliminary/working diagnosis of MCAS per Consensus-2 criteria, pending confirmatory mediator testing (Consensus-1)."
- Exclusion of other causes (pheochromocytoma, carcinoid, hereditary alpha-tryptasemia, systemic mastocytosis) remains mandatory under both frameworks.
PART 7: THE STRUCTURED THERAPEUTIC TRIAL
This is the most accessible diagnostic and therapeutic tool for a rural psychiatrist or PMHNP.
Protocol
Week 0 — Baseline Documentation:
- Complete the MCAS Symptom Screening Checklist (Part 4C)
- Administer PHQ-9, GAD-7, and MoCA
- Have the patient begin a daily symptom diary scoring severity 0–10 across domains (cardiovascular, dermatologic, GI, respiratory, neuropsychiatric)
Week 1 — Start H1 + H2 Blockade:
- Cetirizine 10 mg daily (or fexofenadine 180 mg daily) — nonsedating H1 antihistamine
- Famotidine 20 mg BID — H2 antihistamine
- Continue symptom diary
Week 2–4 — Assess Response:
- Review symptom diary for reduction in frequency or severity
- If partial response: increase H1 antihistamine to 2× standard dose (cetirizine 10 mg BID)
- If no response at 4 weeks: consider adding montelukast 10 mg daily (leukotriene receptor antagonist)
Week 4 — Formal Reassessment:
- Repeat PHQ-9, GAD-7, MoCA
- Compare symptom diary scores to baseline
- Document response quantitatively
Interpreting Results | Response Pattern |Interpretation
Next Steps
Multisystem symptom improvement (≥2 domains) Supports MCAS (Consensus-2 minor criterion met)
Refer to immunology/allergy with documentation
Psychiatric symptom improvement only
May reflect antihistaminic anxiolytic/sedative effect, not necessarily MCAS
Continue treatment; pursue other MCAS testing
No improvement, does not exclude MCAS (some patients require different mediator-targeted therapy)
Consider cromolyn sodium; pursue Consensus-1 testing
PART 8: PSYCHIATRIC ASSESSMENT — PRIMARY VS. SECONDARY
Key Questions to Determine Etiology
1. Temporal relationship: Do psychiatric symptoms fluctuate with physical symptoms?
- Panic attacks coinciding with flushing episodes → suggests mediator-driven
- Anxiety worsening with orthostatic stress → suggests POTS-related
- Depression correlating with flare periods → suggests inflammatory/reactive
2. Treatment response pattern: Did psychiatric symptoms improve with antihistamines before any psychotropic was started?
3. Symptom quality: Does the "anxiety" feel like an internal physiologic surge (adrenaline-like) rather than cognitive worry? This may represent mast cell mediator release or hyperadrenergic POTS rather than generalized anxiety disorder.
4. Cognitive symptoms: Is "brain fog" present? Fluctuating cognitive impairment is atypical for primary depression and suggests an organic/inflammatory etiology.
Validated Instruments to Use
Instrument | Domain | When to Administer
PHQ-9: Depression Baseline and every 4 weeks
GAD-7: Anxiety Baseline and every 4 weeks
MoCA: Cognition Baseline and after therapeutic trial
PCL-5: PTSD (if applicable)
Baseline | Symptom diary | Multisystem tracking |Daily
Assessing for Iatrogenic Harm
Has the "somatoform" label led to:
- Dismissal of symptoms by other providers?
- Delayed diagnosis (years/decades)?
- Psychological trauma from medical gaslighting?
- Healthcare avoidance?
This itself can produce secondary anxiety, depression, and PTSD-like symptoms that require treatment alongside the underlying medical condition.
PART 9: PSYCHOPHARMACOLOGY CONSIDERATIONS
Medications with Dual Benefit (Psychiatric + Antihistaminic)
Medication | Psychiatric Use |Antihistaminic Activity |Notes
Hydroxyzine: Anxiety (FDA-approved), Potent H1 antagonist, Useful bridge; may worsen POTS via sedation
Mirtazapine: Depression, insomnia, Strong H1 antagonist, Weight gain; may help underweight MCAS patients
Doxepin (low-dose): Insomnia, depression, Most potent antihistamine among antidepressants, Use low doses (3–6 mg) for insomnia
Quetiapine (low-dose): Insomnia, anxiety augmentation, H1 antagonist, Caution: may worsen POTS (alpha-blockade)
Medications Recommended for This Population
- SSRIs/SNRIs: Recommended by the 2025 AGA Clinical Practice Update for comorbid mood symptoms in hEDS/POTS/MCAS patients
- Start low, go slow — these patients often have medication sensitivities
Medications to Use with Caution
Medication Class | Concern in This Population
Tricyclics (high-dose): Anticholinergic effects may worsen POTS; tachycardia
Antipsychotics with strong alpha-blockade: May worsen orthostatic symptoms in POTS
Benzodiazepines: May worsen fatigue, cognitive impairment; dependency risk
Bupropion: May worsen anxiety/tachycardia in hyperadrenergic POTS
Medications known to trigger mast cell degranulation
NSAIDs, opioids, certain muscle relaxants, vancomycin
Non-Pharmacologic Interventions
- Brain-gut behavioral therapies (CBT, gut-directed hypnotherapy) — specifically endorsed by the 2025 AGA Clinical
Practice Update
- Stress management and relaxation training
- Graded exercise programs (supervised, starting supine/recumbent for POTS patients)
- Vagus nerve stimulation (transcutaneous auricular VNS is being investigated as a non-invasive option for treatment-resistant depression and inflammatory conditions)
PART 10: DOCUMENTATION AND REFERRAL TEMPLATE
Sample Documentation for Preliminary MCAS Assessment
ASSESSMENT:
Patient presents with episodic multisystem symptoms affecting [list organ systems] with identifiable triggers including [list triggers]. Symptoms have been present for [duration] and have previously been attributed to somatoform disorder/conversion disorder without documented workup for mast cell activation syndrome, postural orthostatic tachycardia syndrome, or Ehlers-Danlos syndrome.
Bedside screening results:
- Beighton Score: ___/9 (positive/negative for generalized joint hypermobility)
- Active Stand Test: Supine HR → Standing HR at minutes (Δ HR = bpm). BP supine / → standing /. [Meets/Does not meet] criteria for POTS.
- MCAS Symptom Screen: Episodic symptoms present in ___/6 organ system domains.
Psychiatric assessment:
- PHQ-9: | GAD-7: | MoCA: ___
- Temporal relationship between psychiatric and physical symptoms: [describe]
Structured therapeutic trial:
- Initiated cetirizine mg daily + famotidine mg BID on [date]
- Symptom diary baseline scores: [list by domain]
- Week 4 reassessment scores: [list by domain]
- Response: [quantified improvement/no change/worsening]
WORKING DIAGNOSIS:
Preliminary diagnosis of Mast Cell Activation Syndrome per Consensus-2 criteria (Afrin et al., 2021), based on:
- Major criterion: Multisystem episodic symptom constellation [met/not met]
- Minor criterion: Symptomatic response to H1/H2 blockade [met/not met]
Pending confirmatory evaluation per Consensus-1 criteria (Valent et al., 2012; AAAAI-endorsed) with mast cell mediator testing.
PLAN:
1. Continue H1/H2 antihistamine therapy
2. Refer to Allergy-Immunology for Consensus-1 confirmation (serum tryptase, 24-hour urine mediators)
3. Refer to Cardiology/Neurology for formal POTS evaluation and autonomic testing
4. Refer to Genetics for EDS evaluation and genetic testing
5. Continue psychiatric management of comorbid [depression/anxiety/insomnia] with [medication/therapy]
6. Follow-up in ___ weeks
PART 11: QUICK-REFERENCE DECISION FLOWCHART
Patient referred to psychiatry as "somatoform" or "conversion disorder"
↓
Step 1: Screen for the triad
- Multisystem episodic symptoms? → MCAS checklist
- Orthostatic symptoms? → Active Stand Test
- Joint hypermobility/chronic pain? → Beighton Score
↓
Step 2: Any screening positive?
- YES → Proceed to Step 3
- NO → Consider primary psychiatric diagnosis, but reassess if treatment-resistant
↓
Step 3: Order available labs
- Serum tryptase (baseline) — available everywhere
- CBC, CMP, TSH, CRP/ESR
- If acute episode occurs: tryptase within 1–4 hours
↓
Step 4: Start structured therapeutic trial
- Cetirizine 10 mg daily + Famotidine 20 mg BID
- Daily symptom diary × 4 weeks
- Repeat PHQ-9, GAD-7, MoCA at week 4
↓
Step 5: Assess and document
- Multisystem improvement → Supports MCAS (Consensus-2)
- Document as preliminary/working diagnosis
- Refer to Allergy-Immunology, Cardiology, Genetics
↓
Step 6: Continue psychiatric care
- Treat comorbid psychiatric symptoms
- Use MCAS-compatible psychopharmacology
- Recommend brain-gut behavioral therapies
- Advocate for the patient across specialties
PART 12: KEY TAKEAWAYS FOR TRAINEES
1. Psychiatry is a diagnostic safety net, not a diagnostic endpoint. When multisystem symptoms are labeled "somatoform" without adequate medical investigation, the psychiatrist is uniquely positioned to recognize the pattern and redirect the diagnostic trajectory.
2. Three bedside tests require no specialized equipment: Beighton Score, Active Stand Test, and MCAS Symptom Screening. Every psychiatry trainee and PMHNP should be able to perform them.
3. Histamine is both an inflammatory mediator and a neurotransmitter. It directly causes anxiety, insomnia, and contributes to depression through multiple mechanisms. Treating the histamine excess may be as important as traditional psychopharmacology.
4. The vagus nerve connects peripheral inflammation to brain function. Reduced vagal tone (as in POTS) weakens the body's anti-inflammatory brake, allowing unchecked neuroinflammation that manifests as psychiatric symptoms.
5. Consensus-2 is a pragmatic bridge, not a final destination. Use it to structure clinical assessment and initiate treatment in resource-limited settings, but always pursue Consensus-1 confirmation through specialist referral.
6. Document everything quantitatively. Symptom diaries, validated instruments, and structured therapeutic trial results create a compelling referral package that is far more likely to result in appropriate specialist evaluation.
7. Start low, go slow with psychopharmacology. These patients often have medication sensitivities. Choose medications with dual benefit (antihistaminic + psychiatric) when possible.
8. Assess for iatrogenic harm. Years of diagnostic dismissal can produce secondary trauma that requires its own treatment.
APPENDIX: SUGGESTED READING
- AAAAI Mast Cell Disorders Committee Work Group Report (Weiler et al., J Allergy Clin Immunol, 2019)
- Consensus-2 Diagnostic Criteria (Afrin et al., Diagnosis, 2021)
- POTS: JACC Focus Seminar (Bryarly et al., J Am Coll Cardiol, 2019)
- AGA Clinical Practice Update on hEDS (Aziz et al., Clin Gastroenterol Hepatol, 2025)
- Mast Cell Activation Disease and Neuropsychiatric Symptoms (Afrin et al., Brain Behav Immun, 2015)
- 2017 International EDS Consortium Diagnostic Criteria
- DSM-5 Somatic Symptom and Related Disorders chapter
References:
AAAAI Mast Cell Disorders Committee Work Group Report: Mast Cell Activation Syndrome (MCAS) Diagnosis and Management. The Journal of Allergy and Clinical Immunology. 2019. Weiler CR, Austen KF, Akin C, et al.Guideline
Diagnosis of Mast Cell Activation Syndrome: A Global "Consensus-2". Diagnosis. 2021. Afrin LB, Ackerley MB, Bluestein LS, et al.Review
Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. Journal of the American College of Cardiology. 2019. Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD.Review
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2025. Aziz Q, Harris LA, Goodman BP, Simrén M, Shin A.Guideline
Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers–Danlos syndrome clinic: A retrospective review. American Journal of Medical Genetics. Part A. 2020. McGillis L, Mittal N, Santa Mina D, et al.
Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing. Genes. 2025. Forghani I, See J, McGonigle WC.
Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association (2022). 2022. Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et alGuideline
Mast Cell Activation Disease: An Underappreciated Cause of Neurologic and Psychiatric Symptoms and Diseases. Brain, Behavior, and Immunity. 2015. Afrin LB, Pöhlau D, Raithel M, et al.Review
The role of inflammation and the gut microbiome in depression and anxiety. Journal of Neuroscience Research. 2019. Peirce JM, Alviña K.Review
Inflammation in Psychiatric Disorders: What Comes First?. Annals of the New York Academy of Sciences. 2019. Bauer ME, Teixeira AL.Review
H1-Antihistamines for Primary Mast Cell Activation Syndromes: A Systematic Review. Allergy. 2015. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A.SR
Using the Right Criteria for McAs. Current Allergy and Asthma Reports. 2024. Gulen T.Review
Comments